ENXTPA:DGM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Diagnostic Medical Systems

Executive Summary

Diagnostic Medical Systems S.A. operates in the medical imaging industry in France.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Diagnostic Medical Systems's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DGM has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

1.0%

DGM

2.4%

FR Medical Equipment

1.8%

FR Market


1 Year Return

39.3%

DGM

75.4%

FR Medical Equipment

-4.8%

FR Market

Return vs Industry: DGM underperformed the French Medical Equipment industry which returned 75.4% over the past year.

Return vs Market: DGM exceeded the French Market which returned -4.8% over the past year.


Shareholder returns

DGMIndustryMarket
7 Day1.0%2.4%1.8%
30 Day1.3%4.8%-2.2%
90 Day-5.7%15.7%7.1%
1 Year39.3%39.3%75.9%75.4%-2.8%-4.8%
3 Year-19.6%-19.6%89.2%85.6%10.7%1.2%
5 Year-40.0%-40.0%163.0%154.4%24.8%7.5%

Price Volatility Vs. Market

How volatile is Diagnostic Medical Systems's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Diagnostic Medical Systems undervalued compared to its fair value and its price relative to the market?

1.72x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DGM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DGM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DGM is unprofitable, so we can't compare its PE Ratio to the FR Medical Equipment industry average.

PE vs Market: DGM is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DGM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DGM is good value based on its PB Ratio (1.7x) compared to the FR Medical Equipment industry average (3.1x).


Next Steps

Future Growth

How is Diagnostic Medical Systems forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Diagnostic Medical Systems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Diagnostic Medical Systems performed over the past 5 years?

-38.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DGM is currently unprofitable.

Growing Profit Margin: DGM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DGM is unprofitable, and losses have increased over the past 5 years at a rate of 38% per year.

Accelerating Growth: Unable to compare DGM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DGM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-8%).


Return on Equity

High ROE: DGM has a negative Return on Equity (-21.82%), as it is currently unprofitable.


Next Steps

Financial Health

How is Diagnostic Medical Systems's financial position?


Financial Position Analysis

Short Term Liabilities: DGM's short term assets (€24.0M) exceed its short term liabilities (€22.0M).

Long Term Liabilities: DGM's short term assets (€24.0M) exceed its long term liabilities (€3.5M).


Debt to Equity History and Analysis

Debt Level: DGM's debt to equity ratio (62.4%) is considered high.

Reducing Debt: DGM's debt to equity ratio has increased from 21.8% to 62.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DGM has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: DGM is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Diagnostic Medical Systems's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DGM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DGM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DGM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DGM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DGM's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

€190k

CEO Compensation


CEO

Jean-Paul Ansel

no data

Tenure

€190,000

Compensation

Mr. Jean-Paul Ansel serves as the Chief Executive Officer of Diagnostic Medical Systems S.A. and has been its Chairman since 2010. He serves as a Director of Diagnostic Medical Systems S.A. Mr. Ansel serve ...


CEO Compensation Analysis

Compensation vs Market: Jean-Paul's total compensation ($USD223.95K) is about average for companies of similar size in the French market ($USD313.53K).

Compensation vs Earnings: Jean-Paul's compensation has been consistent with company performance over the past year.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Diagnostic Medical Systems S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Diagnostic Medical Systems S.A.
  • Ticker: DGM
  • Exchange: ENXTPA
  • Founded: 1993
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €25.148m
  • Shares outstanding: 16.12m
  • Website: https://www.dms.com

Number of Employees


Location

  • Diagnostic Medical Systems S.A.
  • 393 rue Charles Lindbergh
  • Mauguio
  • Languedoc-Roussillon
  • 34130
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DGMENXTPA (Euronext Paris)YesOrdinary SharesFREURMay 1998
0RIALSE (London Stock Exchange)YesOrdinary SharesGBEURMay 1998
DGMPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURMay 1998

Biography

Diagnostic Medical Systems S.A. operates in the medical imaging industry in France. It offers radiography/fluoroscopy, retrofit kits, mammography, chest and bone rooms, mobiles, bone densitometry, 3D recon ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/08 22:13
End of Day Share Price2020/08/07 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.